This is a preview of subscription content, log in via an institution to check access.
Reference
Decision Resources. Roche/Chugai's Bitopertin Will Garner Nearly $1.5 Billion in Major-Market Sales in 2022 as the First Approved Treatment for Negative Symptoms in Schizophrenia. Media Release : 22 Aug 2013. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
Bitopertin set to attain $US1.5bn in sales by 2022. PharmacoEcon Outcomes News 686, 11 (2013). https://doi.org/10.1007/s40274-013-0699-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0699-5